Pulmonary air embolism causing RV failure & arrest—via ocular route? A rare case, deep dive, with The CardioNerds. Hypertension isn’t just a part of aging—lifestyle, awareness, and new treatments matter. NAVULTRA registry compares Navitor vs. SAPIEN 3 Ultra in TAVR, revealing key tradeoffs in pacemaker use, PVL, and HF outcomes Walking at a brisk pace may significantly reduce the risk of heart rhythm disorders, new UK Biobank research shows. The presence of a CMP-PLP variant was linked to a 1.6-fold increased risk for cardiomyopathy or heart failure. Controlling multiple health risks may eliminate premature death risk in people with hypertension, a major study finds. Dr. Daniel Judge discusses how the ATTRibute-CM trial marks a turning point in ATTR cardiomyopathy treatment and research. Elevated [Lp(a)] is strongly associated with an increased risk of atherosclerotic cardiovascular disease. A study compared the effects of Mat Pilates on various cardiometabolic risk factors in women who had gone through menopause. The FDA approved the use of Edwards Lifesciences' SAPIEN 3 TAVR platform for patients with severe aortic stenosis. Women with maternal hypertension who birth preterm infants incur a risk for that child having adverse neurodevelopment. Dr. Dan Judge speaks to The CardioNerds about his interpretation of the primary findings from ATTRibute-CM. Dr. Daniel Judge talks to the CardioNerds about a pivotal study in ATTR-CM. A multifaceted approach is necessary to reduce the deaths of smoking-related aortic aneurysms. Many preschool-aged children with congenital heart conditions are not on track for school readiness. The trial drug revealed greater reductions in 24-hour average blood pressure than placebo. The CardioNerds talk about the professional challenges ACHD providers face across the lifespan of congenital heart disease. A multicomponent intervention is effective in improving the management of people with high blood pressure, a study finds. Researchers have begun to uncover the circadian rhythm of myocardial infarction severity. Gender disparities persist in clinical trials related to atrial fibrillation (AF) management.